Mobile

Study to determine the adequate dose of a new medicine omecantiv mecarbil compared to placebo in patients with a heart condition whereby the ability of the heart to pump enough blood to meet the body’...

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-000327-40

Study to determine the adequate dose of a new medicine omecantiv mecarbil compared to placebo in patients with a heart condition whereby the ability of the heart to pump enough blood to meet the body’s need at all times is reduced

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

(i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in subjects with HF and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks of treatment.

Critère d'inclusion

  • Chronic Heart Failure and Left Ventricular Systolic Dysfunction

Liens